Polymorphisms of ABCC5 and NOS3 genes influence doxorubicin cardiotoxicity in survivors of childhood acute lymphoblastic leukemia

M. Krajinovic, J. Elbared, S. Drouin, L. Bertout, A. Rezgui, M. Ansari, M. J. Raboisson, Steven E Lipshultz, L. B. Silverman, S. E. Sallan, D. S. Neuberg, J. L. Kutok, C. Laverdière, D. Sinnett, G. Andelfinger

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Anthracyclines are efficient chemotherapy agents. However, their use is limited by anthracycline-induced cardiotoxicity (CT). We investigated the influence of polymorphisms in doxorubicin metabolic and functional pathways on late-onset CT as estimated by echocardiography in 251 childhood acute lymphoblastic leukemia (cALL) patients. Association analyses revealed a modulating effect of two variants: A-1629 T in ABCC5, an ATP-binding cassette transporter, and G894T in the NOS3 endothelial nitric oxide synthase gene. Individuals with the ABCC5 TT-1629 genotype had an average of 8–12% reduction of ejection (EF) and shortening fractions (SF; EF: P

Original languageEnglish (US)
JournalPharmacogenomics Journal
DOIs
StateAccepted/In press - Sep 8 2015
Externally publishedYes

Fingerprint

Anthracyclines
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Doxorubicin
Survivors
ATP-Binding Cassette Transporters
Nitric Oxide Synthase Type III
Metabolic Networks and Pathways
Genes
Echocardiography
Genotype
Drug Therapy
Cardiotoxicity
factor EF-P

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine
  • Genetics

Cite this

Polymorphisms of ABCC5 and NOS3 genes influence doxorubicin cardiotoxicity in survivors of childhood acute lymphoblastic leukemia. / Krajinovic, M.; Elbared, J.; Drouin, S.; Bertout, L.; Rezgui, A.; Ansari, M.; Raboisson, M. J.; Lipshultz, Steven E; Silverman, L. B.; Sallan, S. E.; Neuberg, D. S.; Kutok, J. L.; Laverdière, C.; Sinnett, D.; Andelfinger, G.

In: Pharmacogenomics Journal, 08.09.2015.

Research output: Contribution to journalArticle

Krajinovic, M, Elbared, J, Drouin, S, Bertout, L, Rezgui, A, Ansari, M, Raboisson, MJ, Lipshultz, SE, Silverman, LB, Sallan, SE, Neuberg, DS, Kutok, JL, Laverdière, C, Sinnett, D & Andelfinger, G 2015, 'Polymorphisms of ABCC5 and NOS3 genes influence doxorubicin cardiotoxicity in survivors of childhood acute lymphoblastic leukemia', Pharmacogenomics Journal. https://doi.org/10.1038/tpj.2015.63
Krajinovic, M. ; Elbared, J. ; Drouin, S. ; Bertout, L. ; Rezgui, A. ; Ansari, M. ; Raboisson, M. J. ; Lipshultz, Steven E ; Silverman, L. B. ; Sallan, S. E. ; Neuberg, D. S. ; Kutok, J. L. ; Laverdière, C. ; Sinnett, D. ; Andelfinger, G. / Polymorphisms of ABCC5 and NOS3 genes influence doxorubicin cardiotoxicity in survivors of childhood acute lymphoblastic leukemia. In: Pharmacogenomics Journal. 2015.
@article{a895fe83084f4853861491a76f2286cc,
title = "Polymorphisms of ABCC5 and NOS3 genes influence doxorubicin cardiotoxicity in survivors of childhood acute lymphoblastic leukemia",
abstract = "Anthracyclines are efficient chemotherapy agents. However, their use is limited by anthracycline-induced cardiotoxicity (CT). We investigated the influence of polymorphisms in doxorubicin metabolic and functional pathways on late-onset CT as estimated by echocardiography in 251 childhood acute lymphoblastic leukemia (cALL) patients. Association analyses revealed a modulating effect of two variants: A-1629 T in ABCC5, an ATP-binding cassette transporter, and G894T in the NOS3 endothelial nitric oxide synthase gene. Individuals with the ABCC5 TT-1629 genotype had an average of 8–12{\%} reduction of ejection (EF) and shortening fractions (SF; EF: P",
author = "M. Krajinovic and J. Elbared and S. Drouin and L. Bertout and A. Rezgui and M. Ansari and Raboisson, {M. J.} and Lipshultz, {Steven E} and Silverman, {L. B.} and Sallan, {S. E.} and Neuberg, {D. S.} and Kutok, {J. L.} and C. Laverdi{\`e}re and D. Sinnett and G. Andelfinger",
year = "2015",
month = "9",
day = "8",
doi = "10.1038/tpj.2015.63",
language = "English (US)",
journal = "Pharmacogenomics Journal",
issn = "1470-269X",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Polymorphisms of ABCC5 and NOS3 genes influence doxorubicin cardiotoxicity in survivors of childhood acute lymphoblastic leukemia

AU - Krajinovic, M.

AU - Elbared, J.

AU - Drouin, S.

AU - Bertout, L.

AU - Rezgui, A.

AU - Ansari, M.

AU - Raboisson, M. J.

AU - Lipshultz, Steven E

AU - Silverman, L. B.

AU - Sallan, S. E.

AU - Neuberg, D. S.

AU - Kutok, J. L.

AU - Laverdière, C.

AU - Sinnett, D.

AU - Andelfinger, G.

PY - 2015/9/8

Y1 - 2015/9/8

N2 - Anthracyclines are efficient chemotherapy agents. However, their use is limited by anthracycline-induced cardiotoxicity (CT). We investigated the influence of polymorphisms in doxorubicin metabolic and functional pathways on late-onset CT as estimated by echocardiography in 251 childhood acute lymphoblastic leukemia (cALL) patients. Association analyses revealed a modulating effect of two variants: A-1629 T in ABCC5, an ATP-binding cassette transporter, and G894T in the NOS3 endothelial nitric oxide synthase gene. Individuals with the ABCC5 TT-1629 genotype had an average of 8–12% reduction of ejection (EF) and shortening fractions (SF; EF: P

AB - Anthracyclines are efficient chemotherapy agents. However, their use is limited by anthracycline-induced cardiotoxicity (CT). We investigated the influence of polymorphisms in doxorubicin metabolic and functional pathways on late-onset CT as estimated by echocardiography in 251 childhood acute lymphoblastic leukemia (cALL) patients. Association analyses revealed a modulating effect of two variants: A-1629 T in ABCC5, an ATP-binding cassette transporter, and G894T in the NOS3 endothelial nitric oxide synthase gene. Individuals with the ABCC5 TT-1629 genotype had an average of 8–12% reduction of ejection (EF) and shortening fractions (SF; EF: P

UR - http://www.scopus.com/inward/record.url?scp=84941236436&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941236436&partnerID=8YFLogxK

U2 - 10.1038/tpj.2015.63

DO - 10.1038/tpj.2015.63

M3 - Article

JO - Pharmacogenomics Journal

JF - Pharmacogenomics Journal

SN - 1470-269X

ER -